Fig. 1: CMTM6 is downregulated in tumor tissues and its deficiency predicts poor prognosis in HCC. | Cell Death & Disease

Fig. 1: CMTM6 is downregulated in tumor tissues and its deficiency predicts poor prognosis in HCC.

From: CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma

Fig. 1

A–C CMTM6 mRNA levels of HCC tumor tissues (T) and normal liver tissues (N) as indicated in the liver hepatocellular carcinoma (LIHC) dataset from TCGA database (A) and the public GEO liver cancer datasets GSE45267 (B) and GSE112790 (C). D Results of the qPCR analysis of 34 pairs of HCC tumor tissues and adjacent normal liver tissues. E Representative images and statistical analysis of the Western blotting of 34 pairs of HCC tumor tissues and adjacent normal liver tissues. F Typical IHC images of CMTM6 expression status in HCC tissues. G The percentages of cases of four staining intensities. H Tumor size comparison according to CMTM6 expression status. I The percentages of CMTM6 expression status in early (TNM I + II) and advanced (TNM III + IV) HCC. J Kaplan–Meier analysis of OS (top) and DFS (bottom) according to CMTM6 expression status in 167 HCC patients. K Multivariate analysis of CMTM6 expression and clinical variables in HCC using a Cox-regression model. The error bars represent the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Back to article page